2022
DOI: 10.1016/j.prp.2022.153837
|View full text |Cite
|
Sign up to set email alerts
|

Gliosarcoma with osteosarcomatous component: A case report and short review illustration

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
8
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(8 citation statements)
references
References 31 publications
0
8
0
Order By: Relevance
“…Gliosarcomas with features of osteosarcoma manifest in an analogous way to gliosarcomas with no specific clinical manifestations. They are more common in men than women (8 : 5, respectively) and occur between the 4 th and 7 th decades of life, according to Chen et al [7]. It is noteworthy that among the reported cases, 4 were secondary gliosarcomas and in all 4 cases radiotherapy was used in the postoperative treatment [7].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Gliosarcomas with features of osteosarcoma manifest in an analogous way to gliosarcomas with no specific clinical manifestations. They are more common in men than women (8 : 5, respectively) and occur between the 4 th and 7 th decades of life, according to Chen et al [7]. It is noteworthy that among the reported cases, 4 were secondary gliosarcomas and in all 4 cases radiotherapy was used in the postoperative treatment [7].…”
Section: Introductionmentioning
confidence: 99%
“…Gomori's silver staining, reaction with vimentin antibody. Gliosarcoma occurs only in approximately 2% of patients diagnosed with glioma [2,7,8,11,14,16], more often in men than in women, with a ratio of 1.8 : 1. It usually appears in the fourth to sixth decade of life [1,2].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Gliosarcomas (GS) are rare malignant central nervous system (CNS) tumors that are characterized by a mixture of gliomatous and sarcomatous elements ( 1 ). In the 2016 & 2021 World Health Organization (WHO) classification of tumors of the CNS, GS was classified as a subtype of isocitrate dehydrogenase (IDH)-wildtype GBM ( 2 ) and a variant of GBM ( 3 , 4 ) respectively. Therefore, a similar therapeutic regimen for GS and GBM was recommended by the National Comprehensive Cancer Network (NCCN) ( 5 ) and the European Association of Neuro-Oncology (EANO) ( 6 ) guidelines.…”
Section: Introductionmentioning
confidence: 99%
“…GS carry a poorer prognosis than that of GB. Various lines of differentiation are described in the mesenchymal component, but most commonly fibrosarcomatous and pleomorphic sarcoma are present [2,3]. Osteosarcomatous features are exceedingly rare.…”
Section: Introductionmentioning
confidence: 99%